Skip to main content

Table 1 Univariate and multivariate Cox proportional hazards regression analyses demonstrating the independence of ClockLoss or ClockGain from other clinicopathological features

From: Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies

  Hazard ratio (95% CI) P-value
All gliomas (ClockLost) Univariate
 Q2 vs. Q1 0.393 (0.285–0.543) <0.0001
 Q3 vs. Q1 0.274 (0.193–0.387) <0.0001
 Q4 vs. Q1 0.188 (0.127–0.278) <0.0001
All gliomas (ClockGain) Univariate
 Q2 vs. Q1 1.272 (0.813–1.991) 0.29
 Q3 vs. Q1 2.931 (1.951–4.402) <0.0001
 Q4 vs. Q1 3.961 (2.668–5.882) <0.0001
Astrocytoma (ClockGain) Univariate
 Q2 vs. Q1 0.59 (0.242–1.468) 0.26
 Q3 vs. Q1 1.423 (0.65–3.109) 0.38
 Q4 vs. Q1 3.048 (1.514–6.137) 0.0018
Oligodendroglioma (ClockGain) Univariate
 Q2 vs. Q1 0.947 (0.362–2.474) 0.91
 Q3 vs. Q1 1.184 (0.475–2.951) 0.72
 Q4 vs. Q1 2.764 (1.194–6.400) 0.018
Pan-kidney (ClockLost) Univariate
 Q2 vs. Q1 0.783 (0.547–1.121) 0.18
 Q3 vs. Q1 0.801 (0.568–1.131) 0.21
 Q4 vs. Q1 0.520 (0.352–0.768) 0.001
 TNM staging 2.095 (1.858–2.361) <0.0001
  Multivariate
 Q2 vs. Q1 0.783 (0.543–1.129) 0.18
 Q3 vs. Q1 0.764 (0.537–1.089) 0.14
 Q4 vs. Q1 0.569 (0.383–0.847) 0.0055
 TNM staging 2.085 (1.848–2.354) <0.0001
Pan-kidney (ClockGain) Univariate
 Q2 vs. Q1 1.237 (0.838–1.825) 0.28
 Q3 vs. Q1 1.222 (0.828–1.803) 0.31
 Q4 vs. Q1 1.890 (1.311–2.725) 0.00066
  Multivariate
 Q2 vs. Q1 1.177 (0.790–1.752) 0.42
 Q3 vs. Q1 1.429 (0.961–2.124) 0.078
 Q4 vs. Q1 1.941 (1.333–2.826) 0.00054
 TNM staging 2.092 (1.857–2.357) <0.0001
Clear cell renal cell (ClockLost) Univariate
 Q2 vs. Q1 0.608 (0.416–0.888) 0.01
 Q3 vs. Q1 0.546 (0.361–0.795) 0.0019
 Q4 vs. Q1 0.292 (0.179–0.474) <0.0001
 TNM staging 1.87 (1.641–2.132) <0.0001
  Multivariate
 Q2 vs. Q1 0.653 (0.447–0.955) 0.027
 Q3 vs. Q1 0.667 (0.448–0.993) 0.046
 Q4 vs. Q1 0.433 (0.265–0.708) 0.00085
 TNM staging 1.798 (1.572–2.058) <0.0001
Clear cell renal cell (ClockGain) Univariate
 Q2 vs. Q1 1.243 (0.799–1.933) 0.33
 Q3 vs. Q1 1.001 (0.640–1.564) 0.99
 Q4 vs. Q1 1.775 (1.177–2.678) 0.0062
  Multivariate
 Q2 vs. Q1 1.222 (0.786–1.901) 0.37
 Q3 vs. Q1 1.284 (0.818–2.017) 0.28
 Q4 vs. Q1 1.856 (1.230–2.802) 0.0032
 TNM staging 1.874 (1.642–2.138) <0.0001
Bladder (ClockLost) Univariate
 Q2 vs. Q1 1.088 (0.593–1.999) 0.78
 Q3 vs. Q1 1.478 (0.828–2.640) 0.19
 Q4 vs. Q1 2.081 (1.198–3.614) 0.0093
 TNM staging 1.679 (1.323–2.131) <0.0001
  Multivariate
 Q2 vs. Q1 1.059 (0.577–1.946) 0.85
 Q3 vs. Q1 1.357 (0.759–2.426) 0.31
 Q4 vs. Q1 1.776 (1.018–3.099) 0.043
 TNM staging 1.609 (1.263–2.050) 1.20E−04
Stomach (ClockLost) Univariate
 Q2 vs. Q1 0.761 (0.389–1.485) 0.43
 Q3 vs. Q1 1.143 (0.615–2.127) 0.67
 Q4 vs. Q1 2.155 (1.255–3.702) 0.0054
 TNM staging 1.372 (1.067–1.765) 0.038
  Multivariate
 Q2 vs. Q1 0.731 (0.374–1.428) 0.36
 Q3 vs. Q1 1.133 (0.609–2.107) 0.69
 Q4 vs. Q1 2.070 (1.205–3.557) 0.0084
 TNM staging 1.354 (1.054–1.739) 0.018
Lung (ClockGain) Univariate
 Q2 vs. Q1 1.633 (0.987–2.699) 0.056
 Q3 vs. Q1 1.604 (0.973–2.644) 0.064
 Q4 vs. Q1 2.023 (1.224–3.343) 0.006
 TNM staging 1.597 (1.364–1.870) <0.0001
  Multivariate
 Q2 vs. Q1 1.604 (0.971–2.652) 0.065
 Q3 vs. Q1 1.434 (0.868–2.370) 0.16
 Q4 vs. Q1 1.832 (1.108–3.029) 0.018
 TNM staging 1.584 (1.348–1.861) <0.0001
Pancreas (ClockGain) Univariate
 Q2 vs. Q1 1.791 (0.849–3.779) 0.13
 Q3 vs. Q1 1.602 (0.740–3.470) 0.23
 Q4 vs. Q1 3.034 (1.492–6.168) 0.0022
 TNM staging 1.339 (0.897–1.998) 0.153
  Multivariate
 Q2 vs. Q1 1.712 (0.803–3.652) 0.16
 Q3 vs. Q1 1.584 (0.731–3.430) 0.24
 Q4 vs. Q1 2.890 (1.399–5.970) 0.0042
 TNM staging 1.143 (0.756–1.728) 0.52
  1. Significant P values are marked in italics. Univariate values for TNM staging were in accordance with our previous reports utilising TCGA datasets [69, 70, 72]
  2. CI confidence interval